InvestorsHub Logo
Post# of 252302
Next 10
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

Re: DewDiligence post# 153240

Thursday, 11/29/2012 9:40:18 AM

Thursday, November 29, 2012 9:40:18 AM

Post# of 252302
With Servier picking up the tab, basically XOMA has a free shot on goal in both the ACS and diabetes indications. If either one of them pans out, the company has the ability to reacquire the US/Japan rights. Nice deal.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.